IFNG and acute myeloid leukemia: Wang et al. described that interferon-gamma (IFNγ) signaling was strongly correlated with venetoclax resistance, and treating primary AML cells with IFNγ increased their resistance to venetoclax, suggesting that IFNγ inhibition may be a potential strategy to bypass venetoclax resistance.24